Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Fuji
Argus Health
Boehringer Ingelheim
Merck
Chinese Patent Office
Healthtrust
US Army
Deloitte
Farmers Insurance

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,157,456

« Back to Dashboard

Which drugs does patent 7,157,456 protect, and when does it expire?


Patent 7,157,456 protects XARELTO and is included in one NDA. There has been one Paragraph IV challenge on Xarelto.

This patent has seventy-eight patent family members in forty-six countries.

Summary for Patent: 7,157,456

Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/181,051
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
XARELTO
rivaroxaban
TABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYY TREATMENT OF PULMONARY EMBOLISM (PE)
Janssen Pharms
XARELTO
rivaroxaban
TABLET;ORAL022406-001Jul 1, 2011RXYesNo► Subscribe► SubscribeYY TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Janssen Pharms
XARELTO
rivaroxaban
TABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYY TREATMENT OF PULMONARY EMBOLISM (PE)
Janssen Pharms
XARELTO
rivaroxaban
TABLET;ORAL022406-002Nov 4, 2011RXYesNo► Subscribe► SubscribeYY TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Janssen Pharms
XARELTO
rivaroxaban
TABLET;ORAL022406-003Nov 4, 2011RXYesYes► Subscribe► SubscribeYY TREATMENT OF PULMONARY EMBOLISM (PE)
Janssen Pharms
XARELTO
rivaroxaban
TABLET;ORAL022406-003Nov 4, 2011RXYesYes► Subscribe► SubscribeYY TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,157,456

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 62 924Dec 24, 1999
PCT Information
PCT FiledDecember 11, 2000PCT Application Number:PCT/EP00/12492
PCT Publication Date:July 05, 2001PCT Publication Number: WO01/47919

Non-Orange Book Patents for Patent: 7,157,456

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,576,111Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
8,530,505Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
7,592,339Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
8,822,458Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
7,585,860Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
8,129,378Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,157,456

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI277615► Subscribe
Taiwan200422299► Subscribe
TaiwanI226330► Subscribe
Turkey200401314► Subscribe
Turkey200201636► Subscribe
El Salvador2002000245► Subscribe
Slovakia287272► Subscribe
Slovakia9082002► Subscribe
Slovenia1526132► Subscribe
Slovenia1261606► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Healthtrust
Moodys
Daiichi Sankyo
Cerilliant
McKinsey
Argus Health
Colorcon
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot